CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
Bharat Forge Ltd. 25/07/20241,593.85952.3007/04/2025 -40.25% 256 days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Lupin launches Posaconazole delayed-release tablets for treating invasive fungal infections
Apurva Joshi
/ Categories: Trending, Mindshare

Lupin launches Posaconazole delayed-release tablets for treating invasive fungal infections

Lupin Limited’s alliance partner, AET Pharma US Inc (a part of Tiefenbacher Group) has received an approval for its ANDA from United States Food & Drug Administration (USFDA). Post which, Lupin launched Posaconazole delayed-release tablets, 100 mg. 

Posaconazole delayed-release tablets (100 mg) are the generic equivalent of Noxafil delayed-release tablets (100 mg) of Merck Sharp & Dohme Corp. These tablets are indicated for prophylaxis of invasive Aspergillus and Candida infections in patients, who are at a higher risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy. 

As per the data provided by IQVIA MAT for December 2020, Posaconazole delayed-release tablets, 100 mg had estimated annual sales of USD 186 million in the US. 

On the financial front, during December 2020 quarter, the company delivered 3 per cent QoQ growth in India formulations business and 4 per cent QoQ growth in the US business with continuous ramp up of Albuterol. In FY22, it plans to bring three products in the US namely, Albuterol, Perforomist, Brovana along with Fostair in Europe. 

During Wednesday’s morning trading session, the stock of Lupin was trading lower by 2.1 per cent at Rs 1,073.20 from its previous close of Rs 1,095.80 on BSE. 

Previous Article Five stocks with selling interest
Next Article Five stocks with buying interest
Print
870 Rate this article:
4.5
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR